Thursday, November 5, 2015
The San Antonio 1000 Cancer Genomes Project (SA1kCGP), Shanghai-based WuXi NextCODE and South Texas Accelerated Research Therapeutics (START) have partnered to enable San Antonio’s pioneering citywide cancer genomics effort to contribute directly to improving the clinical treatment of cancer around the globe. The SA1kCGP brings together hundreds of doctors, oncologists and surgeons, and a thousand patients to create the basis for the resource: tumor samples from breast, lung, prostate, skin, colorectal, uterine, pancreatic, ovarian, stomach, brain cancers, collected at the time of diagnosis.
WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and Sidra Medical and Research Center, a Doha, Qatar-based hospital, research and education institution, have formed a long-term agreement to provide and co-develop comprehensive research and bioinformatics programs.
WuXi NextCODE, a precision medicine company using the genome to improve health worldwide, and the Children’s Hospital of Fudan University (CHFU), based in Shanghai, have partnered to advance precision medicine in China. It brings WuXi NextCODE’s genomic testing capabilities directly into clinical use for the first time in China, and builds on CHFU’s preeminence in pediatrics to immediately begin delivering benefits to thousands of rare disease patients across China.
Johnson & Johnson Innovation has announced 17 new collaborations with research institutions and healthcare companies, bringing the total number of collaborations formed since the 2013 launch of Johnson & Johnson Innovation to more than 200. Johnson & Johnson Innovation seeks to identify and advance scientific innovation across the Johnson & Johnson segments of Pharmaceutical, Medical Devices and Consumer businesses.
Global CRO WuXi AppTec has partnered with China’s Fudan University to bring WuXi NextCODE‘s population human genomics database system and integrated research and clinical solutions to the Fudan-led Collaborative Innovation Center of Genetics and Development (CICGD) as an enterprise partner. The partnership will empower CICGD scientists to perform gene sequencing and bioinformatics analysis with unparalleled speed and precision, thereby accelerating research, clinical diagnosis and treatment of rare inherited diseases and malignant tumors.